Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5932_Библиотеки_им_академика_М_И_Перельмана

to their tiny size and limited surface area. Microparticles and nanoparticles can be used to improve vaccination [188]. Active or passive targeting can be used to accom­plish targeted distribution [188]. Alzheimer’s disease is closely associated with human plasma concentrations of beta-amyloid40, beta-amyloid42, and phosphorylated tau protein Thioavin-T (ThT) has been reported as a probe for detecting amyloid in Alz­heimer’s disease senile plaques [179,182]. Many studies show that miRNAs may serve as signicant biomarkers in a wide range of disorders, including cancer, diabetes, car­diovascular disease, aging, asthma, autoimmune disease, renal diseases, and neuro­degenerative diseases [183]. This demonstrates the signicance of microRNAs in the distribution of pharmaceuticals. The nanoparticles were rst produced by emulsion polymerization. Analyses were conducted on the particle size, drug loading capacity, and process yield of poly (n-butyl cyanoacrylate) nanoparticles. Usually, the size of drug-loaded nanoparticles was 40.5 6.9 nm [180]. Mechanisms for drug delivery must be capable of penetrating the arterial wall and entering the interstitium [189]. Only receptor systems capable of transcytosis (the migration of a complex ligand-receptor from the luminal to the abluminal membranes of the endothelial cells) are of interest for drug delivery across the blood-brain barrier (BBB) [189]. Within nanotechnology, the subject of employing gold nanoparticles (AuNPs) to deliver medications is increas­ing quickly. Nontoxic and biocompatible, AuNPs have attracted considerable inter­est as a possible pharmaceutical delivery technique [187]. One benet of genetically encoded nanosensors is that they may drive proteins to particular sites within cells, as proven in an animal model of Alzheimer’s disease [187]. Its genetic programming enables the sensors to be utilized in living cells and targeted to certain subcellular compartments, where concentration variations may be monitored [190]. Hence, appli­cations such as ND assessment may benet from the library of genetically encoded glutamate nanosensors [190]. To effectively treat Alzheimer’s disease, it is necessary to create a non-oral, long-term delivery strategy for donepezil. It has been demon­strated that nanoparticles may transport medications across the BBB to malignan­cies of the central nervous system (CNS), and key characteristics of such tools have been found [189,191]. The detection of high quantities of donepezil in the brain might be a game-changer for Alzheimer’s disease treatment. NPs are tiny enough to be absorbed by cells and pass through capillaries, enabling efcient medication accumu­lation at the body’s chosen target sites [191]. No in-vivo examples of an antibody-coated nanoparticle-based therapy for Alzheimer’s disease that led to complete memory recov­ery have ever been recorded, which is a signicant challenge for the science [186].